9,786 Shares in Danaher Co. (NYSE:DHR) Acquired by K.J. Harrison & Partners Inc

K.J. Harrison & Partners Inc bought a new stake in shares of Danaher Co. (NYSE:DHR) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 9,786 shares of the conglomerate’s stock, valued at approximately $2,264,000.

A number of other institutional investors have also recently modified their holdings of the stock. Banco Santander S.A. bought a new stake in Danaher during the third quarter worth $683,000. First Citizens Bank & Trust Co. raised its stake in Danaher by 0.6% during the fourth quarter. First Citizens Bank & Trust Co. now owns 26,611 shares of the conglomerate’s stock worth $6,156,000 after acquiring an additional 149 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in shares of Danaher by 48.1% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 296,996 shares of the conglomerate’s stock worth $68,707,000 after acquiring an additional 96,395 shares during the last quarter. Parkside Financial Bank & Trust grew its holdings in shares of Danaher by 4.8% during the 3rd quarter. Parkside Financial Bank & Trust now owns 3,080 shares of the conglomerate’s stock valued at $764,000 after purchasing an additional 142 shares during the last quarter. Finally, Keybank National Association OH grew its holdings in shares of Danaher by 0.5% during the 3rd quarter. Keybank National Association OH now owns 553,155 shares of the conglomerate’s stock valued at $137,238,000 after purchasing an additional 2,567 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, SVP Georgeann Couchara sold 2,622 shares of Danaher stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total transaction of $636,280.74. Following the completion of the transaction, the senior vice president now directly owns 4,244 shares in the company, valued at $1,029,891.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Danaher news, CEO Rainer Blair sold 47,175 shares of the firm’s stock in a transaction on Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the transaction, the chief executive officer now directly owns 115,995 shares in the company, valued at approximately $28,908,273.90. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Georgeann Couchara sold 2,622 shares of the company’s stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total transaction of $636,280.74. Following the completion of the sale, the senior vice president now owns 4,244 shares of the company’s stock, valued at approximately $1,029,891.48. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 106,565 shares of company stock worth $26,641,364. Insiders own 11.10% of the company’s stock.

Danaher Stock Up 0.3 %

Shares of NYSE DHR traded up $0.65 during trading on Friday, hitting $246.45. 2,710,445 shares of the company traded hands, compared to its average volume of 2,785,746. The firm has a market capitalization of $182.54 billion, a price-to-earnings ratio of 41.77, a P/E/G ratio of 4.19 and a beta of 0.83. The business’s fifty day moving average is $248.87 and its 200 day moving average is $231.08. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.37 and a current ratio of 1.85. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $259.00.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The business had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.62 billion. During the same period in the prior year, the business earned $2.36 EPS. The firm’s revenue for the quarter was down 2.6% on a year-over-year basis. Equities research analysts predict that Danaher Co. will post 7.64 earnings per share for the current fiscal year.

Danaher Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Thursday, March 28th will be paid a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. The ex-dividend date is Wednesday, March 27th. This is a positive change from Danaher’s previous quarterly dividend of $0.24. Danaher’s payout ratio is 18.31%.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on DHR shares. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Citigroup upped their target price on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a report on Wednesday. Barclays boosted their price target on Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a report on Wednesday. Raymond James raised their price objective on shares of Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a report on Wednesday, January 31st. Finally, Robert W. Baird boosted their target price on shares of Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a report on Wednesday. Six analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and a consensus price target of $270.00.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.